CGEN

CompugenA

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

Quote time unavailable

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

25%

Probability

Target price

$3.60

Analysis reference price unavailable

Analysis 2026-10-29 · RankAlpha Sentiment Codex

Most likely

Base case

50%

Probability

Target price

$2.15

Analysis reference price unavailable

Analysis 2026-10-29 · RankAlpha Sentiment Codex

B-

Bear case

25%

Probability

Target price

$0.90

Analysis reference price unavailable

Analysis 2026-10-29 · RankAlpha Sentiment Codex

The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented

AI sentiment snapshot

Latest data as of 2026-10-29

AI commentary

Compugen's September announcement reiterated the Q1 2027 COM701 timetable, but the packet does not establish a subsequent price reaction or analyst revisions. [#PR-2026-09-22] Company announcement Zero-valued sentiment fields indicate unavailable measurements, not neutral readings. The deterministic prior's 0.906 uncertainty, 0.08 evidence-quality, and 0.03 thesis-change scores favor monitoring rather than a stronger directional call.

RankAlpha Sentiment Codex - 2026-10-29

Open full AI memo

Evidence flagged

small-cap biotech peer set is too weak or includes unrelated comparators for a standard-conviction report

Impact

tentative

Confidence

AI events

2027-03-31eventCOM701 MAIA-ovarian interim analysisHigh impact

Compugen expects interim median progression-free-survival data by Q1 2027 from its randomized, placebo-controlled COM701 maintenance trial. A clear benefit could strengthen the development case; ambiguous or adverse data could sharply weaken it. The probability estimates delivery in the stated window, not clinical success. [#PR-2026-08-03] Compugen results release

2027-12-31catalystRilvegostomig partner-program progressHigh impact

Compugen reported 12 ongoing AstraZeneca Phase 3 rilvegostomig trials, but no dated readout or payment forecast. AstraZeneca's February 2026 filing reports a $65 million Q4 2025 payment for part of Compugen's royalty interest, a potential additional $25 million conditional on a BLA-acceptance milestone payment, and future tiered royalties of up to mid-single digits. These terms do not establish CGEN's current economic exposure or an imminent cash receipt. The date is a monitoring horizon, not company guidance. [#PR-2026-08-03] [#REL-afe560d7-2dfd-40d1-a813-45c703055dd0] Compugen results release AstraZeneca SEC filing

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-10-29 • Updated nightlySource: Internal modelMethodology